Abstract Number: Esoc2026a1703 Diagnostic and Prognostic Value of Cystatin-C Levels in the Hyperacute Phase of Hemorrhagic Stroke

Abstract Background and aims To investigate the diagnostic and prognostic significance of Cystatin-C levels in the hyperacute phase of hemorrhagic stroke (HS) in relation to clinical severity scales. Methods Seventy patients with hemorrhagic stroke without acute or chronic renal failure were enrolled. Stroke severity was assessed using the NIHSS and Glasgow Coma Scale (GCS). Patients were divided into two groups: Group I (n = 45) with arterial hypertension + HS, and Group II (n = 25) with type 2 diabetes mellitus + HS. Statistical analyses included Student’s t-test, Pearson correlation, and ROC curve analysis with area under the curve (AUC). Results In Group I, Cystatin-C levels were 0.764 ± 0.06 mg/L in females and 0.702 ± 0.05 mg/L in males, within the normal range, no statistically significant difference between gender (p = 0.087). In Group II, females had 1.014 ± 0.08 mg/L, males 1.100 ± 0.09 mg/L, significantly higher than Group I (p = 0.001). Cystatin-C levels showed a positive correlation with NIHSS scores (r = 0.59; p 0.001) and a negative correlation with GCS scores (r = –0.55; p 0.001). ROC analysis demonstrated good diagnostic performance for predicting severe HS, with an AUC of 0.79 (95% CI: 0.70–0.88). At a cutoff of 1.0 mg/L, sensitivity was 76%, specificity 72%. Conclusions Cystatin-C levels were significantly elevated in Group II, reflecting micro- and macroangiopathic complications typical of long-standing type 2 diabetes. These findings support Cystatin-C as a reliable biomarker for assessing and predicting severity in hemorrhagic stroke among these patients. Conflict of interest nothing to disclose